NCT06793371Phase 2Recruiting

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-09Estimated

Enrollment · participants60Estimated

Source updated2026-08-27Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Treatments or interventions studied

CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)DrugAlso known as ulacamten
Placebo to match CK-4021586Drug

Primary outcomes · main study measures

Read the study measures

measure: Incidence of early drug discontinuation; description: Incidence of early drug discontinuation observed during dosing of CK 4021586 in patients with HFpEF; timeFrame: 12 weeks; measure: Incidence of LVEF < 40%; description: Incidence of left-ventricular ejection fraction (LVEF) \< 40% observed during dosing of CK-4021586 in patients with HFpEF; timeFrame: 12 weeks; measure: Incidence of AEs; description: Incidence of adverse events observed during dosing of CK-4021586 in patients with HFpEF; timeFrame: 12 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history